US-based Boston Scientific has received CE mark approval for the Vercise Deep Brain Stimulation (DBS) System to treat patients with tremor.

The system can be used to treat most common form of disorder known as essential tremor (ET).

Tremor can be identified by involuntary and rhythmic shaking, associated with difficulty in an activity such as writing or holding and controlling items.

Featuring rechargeable battery, the system has been developed to provide precise neural targeting, which helps physicians to customize therapy for patients with ET.

Boston Scientific neuromodulation president Maulik Nanavaty said: "With the launch of the Vercise DBS System for the treatment of patients with Parkinson’s disease in 2012, for dystonia in 2013, and now for tremor, Boston Scientific continues to demonstrate its commitment to provide more access to DBS therapy to more patients."

The Vercise DBS System received CE Mark and TGA (Australia Therapeutic Goods Administration) approvals to treat Parkinson’s disease.

The system, which also secured CE mark for intractable primary and secondary dystonia, is available in the markets of Europe, Israel, Australia and select countries in Latin America.

The system is under investigation in the US, where the company initiated INTREPID clinical trial in mid 2013 to evaluate the safety and efficacy to treat Parkinson’s disease.